Prolonged infusion of gemcitabine in patients with platinum resistant or refractory recurrent ovarian carcinoma:: A phase II study Of GEICO (Spanish Group for investigation on ovarian cancer).

被引：0
|
作者：
Ojeda, B
Gonzaléz-Martín, A
Mellado, B
Bover, I
Fabregat, X
Rubio, MJ
Alonso, L
Lianes, P
Churruca, C
Poveda, A
机构：
[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[2] Hosp Ramon & Cajal, Madrid, Spain
[3] Hosp Clin Barcelona, Barcelona, Spain
[4] Hosp Sont Llatzer, Palma de Mallorca, Spain
[5] Hosp del Mar, Barcelona, Spain
[6] Hosp Reina Sofia, Cordoba, Spain
[7] Hosp Virgen Victoria, Malaga, Spain
[8] Hosp Mataro, Barcelona, Spain
[9] Hosp Donostia, San Sebastian, Spain
[10] IVO, Valencia, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：479S / 479S
页数：1
相关论文
共 50 条
  • [21] A phase II and pharmacokinetic study of enloplatin in patients with platinum refractory advanced ovarian carcinoma
    Kudelka, AP
    Siddik, ZH
    Tresukosol, D
    Edwards, CL
    Freedman, RS
    Madden, TL
    Rastogi, R
    Hord, M
    Kim, EE
    Tornos, C
    Mante, R
    Kavanagh, JJ
    ANTI-CANCER DRUGS, 1997, 8 (07) : 649 - 656
  • [22] Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: A phase II study of the Gynecologic Oncology Group
    Brewer, Cheryl A.
    Blessing, John A.
    Nagourney, Robert A.
    Morgan, Mark
    Hanjani, Parviz
    GYNECOLOGIC ONCOLOGY, 2006, 103 (02) : 446 - 450
  • [23] PHASE Ⅱ STUDY OF GEMCITABINE COMBINED WITH PLATINUM CHEMOTHERAPY FOR RECURRENT EPITHELIAL OVARIAN CANCER
    Peng Peng
    Chinese Medical Sciences Journal, 2007, (03) : 177 - 182
  • [24] A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer
    Eisenhauer, Eric L.
    Zanagnolo, Vanna
    Cohn, David E.
    Salani, Ritu
    O'Malley, David M.
    Sutton, Gregory
    Callahan, Michael J.
    Cobb, Bobbi
    Fowler, Jeffrey M.
    Copeland, Larry J.
    GYNECOLOGIC ONCOLOGY, 2014, 134 (02) : 262 - 266
  • [25] Phase II exploratory study of brostallicin in patients with ovarian cancer resistant/refractory to platinum-based chemotherapy
    Lorusso, D.
    Zanaboni, F.
    Scalone, S.
    Secomandi, R.
    Ferrandina, G.
    Scambia, G.
    Jannuzzo, M. G.
    Petroccione, A.
    Comis, S.
    Raspagliesi, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer
    Eisenhauer, E.
    Zanagnolo, V.
    Cohn, D.
    Salani, R.
    O'Malley, D.
    Sutton, G.
    Cobb, B.
    Vaughan, M.
    Fowler, J.
    Copeland, L.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S31 - S31
  • [27] A FEASIBILITY STUDY OF GEMCITABINE AND BEVACIZUMAB IN WOMEN WITH PLATINUM-RESISTANT RECURRENT OVARIAN CANCER
    Nagao, S.
    Kogiku, A.
    Ota, M.
    Yamamoto, K.
    Narita, M.
    Shimada, K.
    Nagazawa, H.
    Shibutani, T.
    Yamamoto, K.
    Jimi, T.
    Yano, H.
    Kitai, M.
    Shiozaki, T.
    Matsuoka, K.
    Yamaguchi, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A501 - A501
  • [28] Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
    Walsh, Christine S.
    Kamrava, Mitchell
    Rogatko, Andre
    Kim, Sungjin
    Li, Andrew
    Cass, Ilana
    Karlan, Beth
    Rimel, Bobbie J.
    PLOS ONE, 2021, 16 (06):
  • [29] Preliminary results of a Phase II study of the combination of biweekly cisplatin (CDDP) and gemcitabine in patients with platinum refractory advanced ovarian carcinoma
    Efstathiou, Eleni
    ANNALS OF ONCOLOGY, 2004, 15 : 131 - 131
  • [30] Weekly gemcitabine in patients with relapsed platinum-resistant ovarian or peritoneal cancer. Results of phase II study
    Czerniawska, Malgorzata
    Jagiello-Gruszfeld, Agnieszka
    Zbrzezniak, Jolanta
    Wachula, Ewa
    Szablowska-Siwik, Sylwia
    Sikorska, Magdalena
    ANNALS OF ONCOLOGY, 2006, 17 : 172 - 172
12345